{
    "root": "0deddc26-2764-4879-a0e4-a29fff246244",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Alprazolam",
    "value": "20250115",
    "ingredients": [
        {
            "name": "ALPRAZOLAM",
            "code": "YU55MQ3IZY",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_2611"
        },
        {
            "name": "POWDERED CELLULOSE",
            "code": "SMD1X3XO9M"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "DOCUSATE SODIUM",
            "code": "F05Q2T2JA0",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11089"
        },
        {
            "name": "LACTOSE, UNSPECIFIED FORM",
            "code": "J2B2A4N98G",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_113455"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        }
    ],
    "indications": {
        "text": "alprazolam indicated : \u2022acute treatment generalized anxiety disorder ( gad ) adults . \u2022treatment panic disorder ( pd ) , without agoraphobia adults .",
        "doid_entities": [
            {
                "text": "generalized anxiety disorder (DOID:14320)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_14320"
            },
            {
                "text": "anxiety (DOID:2030)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2030"
            },
            {
                "text": "panic disorder (DOID:594)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_594"
            },
            {
                "text": "agoraphobia (DOID:593)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_593"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 generalized anxiety disorder : ( 2.1 ) recommended starting oral 0.25 mg 0.5 mg three times daily . may increased , intervals every 3 4 days , maximum recommended daily dose 4 mg , given divided doses . lowest possible effective dose frequently assess need continued treatment . \u2022 panic disorder : recommended starting oral 0.5 mg three times daily . may increased intervals every 3 4 days increments 1 mg per day . ( 2.2 ) \u2022 tapering , decrease 0.5 mg every 3 days . patients may require even slower reduction . ( 2.3 , 5.2 ) \u2022 full prescribing information recommended geriatric patients , patients hepatic impairment , ritonavir . ( 2.4 , 2.5 , 2.6 )",
        "doid_entities": [
            {
                "text": "generalized anxiety disorder (DOID:14320)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_14320"
            },
            {
                "text": "anxiety (DOID:2030)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2030"
            },
            {
                "text": "panic disorder (DOID:594)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_594"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "alprazolam tablets , usp supplied following strengths package configurations : alprazolam tablets packageconfiguration tablet strength ( mg ) ndc print bottles 100 bottles 500 bottles 1000 0.25 mg ndc 59762-3719-1 ndc 59762-3719-3 ndc 59762-3719-4 white , oval , scored , imprinted \u201c g3719 \u201d bottles 100 bottles 500 bottles 1000 0.5 mg ndc 59762-3720-1 ndc 59762-3720-3 ndc 59762-3720-4 peach , oval , scored , imprinted \u201c g3720 \u201d bottles 100 bottles 500 bottles 1000 1 mg ndc 59762-3721-1 ndc 59762-3721-3 ndc 59762-3721-4 blue , oval , scored , imprinted \u201c g3721 \u201d bottles 100 bottles 500 2 mg ndc 59762-3722-1 ndc 59762-3722-3 white , oblong , multi-scored , imprinted \u201c g3722 \u201d store controlled room temperature 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "alprazolam contraindicated patients : \u2022with known hypersensitivity alprazolam benzodiazepines . angioedema reported [ ( 6.2 ) ] . \u2022taking strong cytochrome p450 3a ( cyp3a ) inhibitors ( e.g . , ketoconazole , itraconazole ) , except ritonavir [ ( 2.6 ) , ( 5.5 ) , ( 7.1 ) ]",
    "indications_original": "Alprazolam is indicated for the:\n                  \n                     \n                        \u2022acute treatment of generalized anxiety disorder (GAD) in adults. \n                     \n                        \u2022treatment of panic disorder (PD), with or without agoraphobia in adults.",
    "contraindications_original": "\u2022 Generalized Anxiety Disorder : ( 2.1 ) o Recommended starting oral dosage is 0.25 mg to 0.5 mg three times daily. o Dosage may be increased, at intervals of every 3 to 4 days, to a maximum recommended daily dose of 4 mg, given in divided doses. o Use the lowest possible effective dose and frequently assess the need for continued treatment. \u2022 Panic Disorder : Recommended starting oral dosage is 0.5 mg three times daily. The dosage may be increased at intervals of every 3 to 4 days in increments of no more than 1 mg per day. ( 2.2 ) \u2022 When tapering, decrease dosage by no more than 0.5 mg every 3 days. Some patients may require an even slower dosage reduction. ( 2.3 , 5.2 ) \u2022 See the Full Prescribing Information for the recommended dosage in geriatric patients, patients with hepatic impairment, and with use with ritonavir. ( 2.4 , 2.5 , 2.6 )",
    "warningsAndPrecautions_original": "Alprazolam Tablets, USP are supplied in the following strengths and package configurations:\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Alprazolam Tablets\n                              \n                           \n                        \n                        \n                           \n                              \n                                 PackageConfiguration\n                              \n                           \n                           \n                              \n                                 Tablet Strength (mg)\n                              \n                           \n                           \n                              \n                                 NDC\n                              \n                           \n                           \n                              \n                                 Print\n                              \n                           \n                        \n                        \n                           \n                              Bottles of 100\n                              Bottles of 500\n                              Bottles of 1000\n                           \n                           \n                              0.25 mg\n                           \n                           \n                              NDC 59762-3719-1\n                              NDC 59762-3719-3\n                              NDC 59762-3719-4\n                           \n                           \n                              white, oval, scored, imprinted \u201cG3719\u201d\n                           \n                        \n                        \n                           \n                              Bottles of 100\n                              Bottles of 500\n                              Bottles of 1000\n                           \n                           \n                              0.5 mg\n                           \n                           \n                              NDC 59762-3720-1\n                              NDC 59762-3720-3\n                              NDC 59762-3720-4\n                           \n                           \n                              peach, oval, scored, imprinted \u201cG3720\u201d\n                           \n                        \n                        \n                           \n                              Bottles of 100\n                              Bottles of 500\n                              Bottles of 1000\n                           \n                           \n                              1 mg\n                           \n                           \n                              NDC 59762-3721-1\n                              NDC 59762-3721-3\n                              NDC 59762-3721-4\n                           \n                           \n                              blue, oval, scored, imprinted \u201cG3721\u201d\n                           \n                        \n                        \n                           \n                              Bottles of 100\n                              Bottles of 500\n                           \n                           \n                              2 mg\n                           \n                           \n                              NDC 59762-3722-1\n                              NDC 59762-3722-3\n                           \n                           \n                              white, oblong, multi-scored, imprinted \u201cG3722\u201d\n                           \n                        \n                     \n                  \n                  Store at controlled room temperature 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Alprazolam is contraindicated in patients:\n                  \n                     \n                        \u2022with known hypersensitivity to alprazolam or other benzodiazepines. Angioedema has been reported [see Adverse Reactions (6.2)].\n                     \n                        \u2022taking strong cytochrome P450 3A (CYP3A) inhibitors (e.g., ketoconazole, itraconazole), except ritonavir [see Dosage and Administration (2.6), Warnings and Precautions (5.5), Drug Interactions (7.1)]",
    "drug": [
        {
            "name": "Alprazolam",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_2611"
        }
    ]
}